In June, CombiGene and Spark Therapeutics held a bi-annual Joint Research Committee meeting in Stockholm, Sweden,
CombiGene AB (“CombiGene”, the “Company”) today announces that CEO Jan Nilsson will leave his position as
In January 2023, CombiGene AB (“CombiGene”, the “Company”) and the Danish company Zyneyro ApS announced a
Read CombiGene’s newsletter in English here or download the attachement. Ingeneious issue no 3 2023 Contacts
The following resolutions were passed at the annual general meeting (the “AGM”) of CombiGene AB (publ)
Read CombiGene’s newsletter in English here or download the attachement. Contacts Jan Nilsson, CEO Phone: +46
Vinnova supports the formation of a Nordic CCRM hub Vinnova, Sweden’s Innovation Agency, has granted funding
Since the beginning of 2023, CombiGene and the Danish company Zyneyro have jointly developed the pain
The shareholders of CombiGene AB (publ) reg. no. 556403-3818 (the “Company”) are hereby summoned to attend
STOCKHOLM — On April 7, 2023, Esbjörn Melin, Industrial Post doc at CombiGene, together with researchers